Medtech player Healthium acquires CareNow
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
The drug is also intended for the treatment of glioblastoma multiforme
Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The facility has the capacity to produce one crore doses per day
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
Subscribe To Our Newsletter & Stay Updated